Skip to main content

Advertisement

ADVERTISEMENT

Medication Treatments

News
06/15/2022
The longer individuals with opioid use disorder engage in medication-assisted treatment, the less likely they are to overdose, according to a new study of Medicaid beneficiaries.
The longer individuals with opioid use disorder engage in medication-assisted treatment, the less likely they are to overdose, according to a new study of Medicaid beneficiaries.
The longer individuals with...
06/15/2022
Addiction Professional
News
06/08/2022
COVID-19-related changes to buprenorphine prescribing guidelines improved opioid use disorder patient outcomes, according to Drexel University researchers.
COVID-19-related changes to buprenorphine prescribing guidelines improved opioid use disorder patient outcomes, according to Drexel University researchers.
COVID-19-related changes to...
06/08/2022
Psych Congress Network
News
05/20/2022
ICEERS has partnered with Sant Joan de Reus University Hospital to conduct a clinical trial of a novel ibogaine treatment protocol to support patients tapering off methadone.
ICEERS has partnered with Sant Joan de Reus University Hospital to conduct a clinical trial of a novel ibogaine treatment protocol to support patients tapering off methadone.
ICEERS has partnered with Sant...
05/20/2022
Psych Congress Network
Heather Bell, MD, and Kurt DeVine, MD
Videos
05/17/2022
Kurt DeVine, MD, and Heather Bell, MD, family and addiction physicians at Stratis Health, CentraCare, explain how Project ECHO has increased access to care for many people in rural and underserved areas throughout Minnesota.
Kurt DeVine, MD, and Heather Bell, MD, family and addiction physicians at Stratis Health, CentraCare, explain how Project ECHO has increased access to care for many people in rural and underserved areas throughout Minnesota.
Kurt DeVine, MD, and Heather...
05/17/2022
Psychiatry & Behavioral Health
News
05/14/2022
The findings could help clinicians identify risk factors for precipitated withdrawal during buprenorphine induction and inform future treatment approaches.
The findings could help clinicians identify risk factors for precipitated withdrawal during buprenorphine induction and inform future treatment approaches.
The findings could help...
05/14/2022
Addiction Professional
News
05/10/2022
In a recent pharmacodynamic study, Opiant Pharmaceuticals’ OPNT003, nasal nalmefene, was found to produce a respiratory depression reversal nearly twice that of nasal naloxone in topline results released by the company.
In a recent pharmacodynamic study, Opiant Pharmaceuticals’ OPNT003, nasal nalmefene, was found to produce a respiratory depression reversal nearly twice that of nasal naloxone in topline results released by the company.
In a recent pharmacodynamic...
05/10/2022
Addiction Professional
News
04/18/2022
Creating a hybrid approach to recovery that incorporates medication-assisted and abstinence-based forms of treatment provides patients with more options and improves retention, say Robert L. DuPont, MD, and Cara Poland, MD, MEd.
Creating a hybrid approach to recovery that incorporates medication-assisted and abstinence-based forms of treatment provides patients with more options and improves retention, say Robert L. DuPont, MD, and Cara Poland, MD, MEd.
Creating a hybrid approach to...
04/18/2022
Psychiatry & Behavioral Health
News
03/29/2022
As drug overdose deaths nationally increased to more than 100,000 per year for the first time, growth in the use of medications to treat opioid use disorder stalled during the COVID-19 pandemic, according to new research from RTI...
As drug overdose deaths nationally increased to more than 100,000 per year for the first time, growth in the use of medications to treat opioid use disorder stalled during the COVID-19 pandemic, according to new research from RTI...
As drug overdose deaths...
03/29/2022
Addiction Professional
News
03/24/2022
Vista Research Group has received a $250,000 grant from Conquer Addiction Research Institute (CARI), the newly created research arm of the not-for-profit Conquer Addiction, to conduct a longitudinal outcomes study of patients who attend...
Vista Research Group has received a $250,000 grant from Conquer Addiction Research Institute (CARI), the newly created research arm of the not-for-profit Conquer Addiction, to conduct a longitudinal outcomes study of patients who attend...
Vista Research Group has...
03/24/2022
Addiction Professional
News
03/22/2022
More than two-thirds of patients who receive medication to treat opioid use disorder in emergency departments do not sustain their treatment, according to a new study published by the RAND Corporation.
More than two-thirds of patients who receive medication to treat opioid use disorder in emergency departments do not sustain their treatment, according to a new study published by the RAND Corporation.
More than two-thirds of patients...
03/22/2022
Addiction Professional

Advertisement

Advertisement